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Abstract
Background: The study of relationships between human diseases provides new possibilities for biomedical
research. Recent achievements on human genetic diseases have stimulated interest to derive methods to identify
disease associations in order to gain further insight into the network of human diseases and to predict disease
genes.
Results: Using about 10000 manually collected causal disease/gene associations, we developed a statistical
approach to infer meaningful associations between human morbidities. The derived method clustered
cardiometabolic and endocrine disorders, immune system-related diseases, solid tissue neoplasms and
neurodegenerative pathologies into prominent disease groups. Analysis of biological functions confirmed
characteristic features of corresponding disease clusters. Inference of disease associations was further employed as
a starting point for prediction of disease genes. Efforts were made to underpin the validity of results by relevant
literature evidence. Interestingly, many inferred disease relationships correspond to known clinical associations and
comorbidities, and several predicted disease genes were subjects of therapeutic target research.
Conclusions: Causal molecular mechanisms present a unifying principle to derive methods for disease
classification, analysis of clinical disorder associations, and prediction of disease genes. According to the definition
of causal disease genes applied in this study, these results are not restricted to genetic disease/gene relationships.
This may be particularly useful for the study of long-term or chronic illnesses, where pathological derangement
due to environmental or as part of sequel conditions is of importance and may not be fully explained by genetic
background.
Background
Diseases and accompanying symptoms are spawned by
systems of molecules, which operate within and across
cell and tissue boundaries. A major goal of medical
research is to identify the molecular components which
play a role in causing a pathological condition. Since
first seminal achievements [1], events at the molecular
level have been recognized as key to understand disease
mechanisms.
Phenotype/genotype associations provide evidence for
a role of affected gene products in respective causal
mechanisms and extensive resources document medi-
cally relevant gene variants [2,3]. Recent studies on her-
editary phenotypes have shown that similarities among
disorders imply involvement of functionally related gene
products, summarized as “phenotypic overlap implies
genetic overlap”. The modular nature of human genetic
diseases suggests that modules of similar disorders, also
denoted as disease subnetworks, can be juxtaposed with
modules of molecules which commonly contribute to a
biological function, or interact in molecular complexes
or pathways [4-7]. Several studies support the modular-
ity concept and it was successfully applied to derive
computational approaches for prediction of candidate
genes as well as functional links between molecules
[8-12].
It is now clear that analysis of disease relationships
unfolds new opportunities for both medical and biologi-
cal research. Several aforementioned works determined
pairwise disorder similarity with a score derived from
text-mining of OMIM phenotype descriptions [5].
Rzhetsky et al. [9] analyzed associations among 161 dis-
eases based on their co-occurrence in patient records.
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action networks or molecular pathways were also
explored [13,14]. Sam et al. [13] used relations between
proteins, Gene Ontology (GO) [15], and phenotypes
established in the PhenoGO NLP system [16] together
with Reactome [17] protein interactions to find diseases
involving common protein-protein interaction networks
such as xeroderma pigmentosum and Cockayne syn-
drome, for which a functional link was previously dis-
cussed [18]. Li and Agarwal [14] obtained disease/gene
associations through literature mining of MEDLINE
abstracts and constructed a network of diseases which
share common molecular pathways. In this network
they identified novel disease relationships and observed
that a disease is linked to several pathways and a path-
way is linked to several diseases.
We present a novel approach to analyze mechanistic
relationships between human diseases. Using about
10000 causal disease/gene associations annotated in the
BIOBASE Knowledge Library (BKL) [19] a statistical
method that quantifies pairwise similarity between disor-
ders was developed. Connecting diseases at a certain sig-
nificance threshold, the statistical approach revealed
groups of diseases which feature characteristic biological
functions. So far, computationally inferred disease rela-
tionships were mainly examined with regard to shared
molecular networks. Yet, many disease associations
reported in this work correspond to known clinical asso-
ciations and causal links between pathologies. Further-
more, we used disease associations and gene
associations to predict causal disease genes. The results
suggest that analysis of causal mechanisms provides a
unified framework for disease classification, discovery of
causal components, and can be used to obtain computa-
tional evidence for clinical disease associations as well as
hypotheses about their molecular foundation.
Results
A molecular mechanistic map of human diseases
We extracted disease/gene associations which had been
manually classified as causal or preventative from the
BIOBASE Knowledge Library™ (Methods). In the follow-
ing, we denote respective genes as causal genes.T h e
data set comprised 375 diseases which were connected
to at least 5 of 3051 causal genes by a total of 9871 dis-
ease/gene associations. Similarity of involved molecular
mechanisms for each disease pair was assessed by calcu-
lating the number of common causal genes and the cor-
responding P-value as described in Methods.
We first constructed a map connecting all diseases
with a minimum of two common genes and a maximal
similarity P-value of 0.001. This map consisted of one
giant component with 123 disease nodes, three med-
ium-sized components with 14, 12, and 10 nodes as well
as 29 small components with two to six nodes. In total,
there were 239 of the 375 diseases, so that 136 diseases
were not connected to any other at the required similar-
ity threshold.
We tested whether the number of 239 diseases con-
nected at the chosen P-value threshold was statistically
significant. For this, we calculated false discovery rates
(FDR) for P-values of disease pairs with at least two
common causal genes using the fdrtool package [20].
According to fdrtool, the P-value cut-off 0.001 corre-
sponded to a false discovery rate of 0.024. Hence, the
disease connections were statistically significant also
after multiple testing correction. For comparison, 282
disorders were connected at a FDR of 0.05 (P-value
3.73e-3).
F i g .1a n dF i g .2s h o wt h eg i a n tc o m p o n e n ta n dt h e
three medium-sized components.
In the giant component, diseases are congregated in
three subregions. The top of the network (yellow
colored, Fig. 1) comprises mostly muscular, cardiovas-
cular and metabolic diseases such as diabetic disorders,
obesity, myopathies and heart failure, but also stroke
and brain ischemia. Many of the disease entities gath-
ered in this region are recognizable as components of
the cardiometabolic syndrome, a clinical clustering of
cardiovascular disease risk factors like obesity, hyper-
tension, and insulin resistance [21,22]. Notably, two
neoplastic diseases, namely parathyroid neoplasms and
pituitary neoplasms (orange nodes), are located in a
branch shared with acromegaly, adenoma, hyperpar-
athyroidism, and hypoparathyroidism (yellow nodes).
Acromegaly is an endocrine disorder which is caused
in more than 95% of the cases by benign, growth hor-
mone producing pituitary adenoma [23]. Other endo-
crine neoplasia such as parathyroid neoplasms can
occur as part of an acromegaly-causing syndrome
called multiple endocrine neoplasia (MEN) [24].
Hence, this branch involves endocrine disorders and
known comorbidities.
Through thrombosis and thrombocytopenia, also
connected to the more general class of blood platelet
disorders, the top region is joined with an area contain-
ing hematological malignancies like leukemia and lym-
phoma (red nodes, Fig. 1) as well as several other
immune system-related pathologies among others multi-
ple sclerosis, acquired immunodeficiency syndrome, and
rheumatoid arthritis (purple nodes, Fig. 1). The third
subregion of the giant component contains exclusively
non-hematological malignancies like liver neoplasms,
brain neoplasms, and melanoma (orange colored, Fig. 1).
The connection to the central part of the component
occupied by immune system-related disorders occurs
through hepatocellular carcinoma and glioma, which are
linked with multiple myeloma.
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Page 2 of 19Figure 1 Giant component of the human disease map. The giant component of the disease map comprised 123 disease nodes (yellow,
orange, red, and purple nodes) arranged in three subregions. Some disease names are highlighted. The top region (yellow and orange nodes)
contains muscular, cardiovascular and metabolic disorders as well as parathyroid neoplasms and pituitary neoplasms. The middle region is made
up of hematological malignancies (red nodes) and immune system-related pathologies such as multiple sclerosis, acquired immunodeficiency
syndrome, and rheumatoid arthritis (purple nodes), whereas non-hematological malignancies are located in the lower region (orange nodes).
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sent developmental abnormalities, audio-visual disorders
as well as neurodegenerative and psychiatric illnesses.
One cluster (Fig. 2A) concatenates, among others, var-
iants of congenital mental retardation, eye abnormalities,
tooth abnormalities as well as glaucoma, cataract and
renal tubular acidosis. Retinal diseases, blindness as well
as hearing loss and deafness are located together in
another group (Fig. 2B). In the third disease group (Fig.
2C), we find Parkinsonian disorders, Alzheimer disease,
dementia, as well as bipolar disorder and alcoholism.
Several of the smaller disease groups (Additional file 1)
reflect the hierarchy of MeSH headings which are used
for BKL disease annotation, e.g. hepatitis descriptors
(group 7), ataxias (group 14), osteoporosis and postme-
nopausal osteoporosis (group 21), and growth disorders
and dwarfism (group 31). The link between xeroderma
pigmentosum and Cockayne syndrome (group 10) as
well as their connection to the hair disease Trichothio-
dystrophy were previously discussed [13,18,25,26].
To examine whether the revealed disease associations
reflect common causal mechanisms, we compared GO
assignments of genes in the six largest disease groups.
The Gene Ontology [15] is an extensive resource of
functional annotations of genes in three main categories
Biological Process, Molecular Function and Cellular
Component. The Fisher test is typically used to test for
significant enrichment of GO categories in gene sets
(Methods). Starting from enrichment P-values obtained
with the standard test, we assigned GO biological pro-
c e s s e st od i s e a s eg r o u p si d e n t i f i e di nt h i sw o r ka n d
ranked them by a preponderance value that compares
P-values of different gene sets (Methods). Beyond
identification of significantly enriched biological func-
tions, this comparative approach enables to detect func-
tional differences between gene sets even when the
standard method does not assign top ranks to respective
GO categories. The analysis was performed on six dis-
ease groups. We explored functional differences between
disease clusters using curated GO annotation from the
BKL. Calculation of preponderance values and GO term
assignments were also performed with enrichment P-
values reported by the DAVID Functional Annotation
Tool [27,28] as a public source of GO annotation. The
first three groups used in the analysis match regions of
the giant component: the top region mainly comprising
cardiometabolic diseases also including parathyroid and
pituitary neoplasms, the middle region constituted of
leukemia, lymphoma, and immune system-related
pathologies, as well as the lower region with solid tissue
neoplasms (Fig. 1). In the following, we denote these
groups as clusters M, I, and C, respectively. The other
three disease groups were obtained from networks
s h o w ni nF i g .2 ,a n da r ei nt h ef o l l o w i n gd e n o t e da s
clusters D (Fig. 2A), P (Fig. 2B), and N (Fig. 2C). Enrich-
ment P-values were calculated and compared for com-
plementary sets made up of genes which were specific
for each cluster. Respectively, 337 genes, 279 genes, 683
genes, 107 genes, 82 genes, and 130 genes represented
cluster M, I, C, D, P, and N. All diseases were associated
with at least one gene in corresponding gene sets,
except for transient ischemic attack, so that results only
apply to 62 of 63 disorders in cluster M.
Fig. 3 shows the top 15 GO biological processes of
each disease cluster ranked by preponderance value. Bar
plots indicate the relative importance of a particular
Figure 2 Medium-sized components of the human disease map. The figure shows three medium-sized components of the disease map
with some disease names highlighted. One group (A) comprises variants of congenital mental retardation, eye abnormalities, tooth abnormalities
as well as glaucoma, cataract and renal tubular acidosis. Retinal diseases, blindness as well as hearing loss and deafness are joined in another
group (B). The third disease group (C) contains Parkinsonian disorders, Alzheimer disease, dementia, as well as bipolar disorder and alcoholism.
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Page 4 of 19Figure 3 Preponderant biological functions in disease clusters. For each of the six disease clusters extracted from the disease map, the
figure shows the top 15 GO biological processes ranked by the preponderance value described in the Methods section. This analysis reveals
biological functions which are most strongly associated with a certain disease cluster compared to all other clusters. The most preponderant
gene classes reflect meaningful features of corresponding disease groups, such as metabolic processes in cluster M, cell cycle and apoptosis
functions in cluster C, or genes involved in neurotransmission in cluster N.
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enrichment P-values. These results demonstrate prepon-
derance of certain biological functions in each disease
cluster. Cluster M was characterized by genes with
metabolic and homeostatic functions, whereas immune
system-related functions signified cluster I. Furthermore,
we found preponderance of apoptotic, angiogenetic, cell
cycle and cell developmental functions in cluster C.
Cluster D genes showed strongest tendency to encode
components of specific developmental and morphoge-
netic processes. Finally, the analysis revealed preponder-
ance of genes encoding sensorineural processes in
cluster P, whereas behavioral and neurological functions
were associated with cluster N.
Since the BKL assignments of genes to GO biological
processes are manually curated, we carried out the same
analysis using enrichment P-values calculated by the
DAVID Functional Annotation Tool in order to validate
our results with an alternative source of GO annota-
tions. In Additional file 2 we report the top 30 biological
processes associated with each disease cluster according
to enrichment P-values calculated by the DAVID tool.
The topics of categories assigned to disease clusters
based on GO annotation of DAVID are in good agree-
ment with those observed in the analysis of curated BKL
annotation. A notable difference is the absence of cell
cycle categories among the top 30 biological processes
assigned to cluster C in the analysis using DAVID. Cell
cycle terms were still associated with disease cluster C,
albeit with lower ranks than in the BKL analysis. For
instance, preponderance values calculated for DAVID
enrichment P-values ranked the GO categories “regula-
tion of cell cycle” and “cell cycle” at position 86 and 88
(data not shown), respectively, whereas they were ranked
5
th and 9
th in the BKL analysis (Fig. 3). Nevertheless, the
top ranked biological processes assigned to disease clus-
ter C based on either DAVID or BKL share a common
theme of cell proliferation, apoptosis, angiogenesis and
developmental pathways. Hence, both resources con-
firmed that the disease clusters feature biological pro-
cesses that reflect the type of clustered disorders.
To further explore the relevance of inferred disease
associations, we inspected vicinities of some selected
disorders defined by a certain similarity level. Here, we
made use of the statistical method to extract all diseases
associated with a pathology of interest through at least
two common causal genes and a similarity P-value
below 0.01. In the following, we exemplify three cases of
metabolic disorders, namely type 1 diabetes (T1DM),
type 2 diabetes (T2DM), obesity, and the neurodegen-
erative disorder Parkinson disease (PD).
Table 1 shows vicinal diseases obtained at the speci-
fied similarity level. While the metabolic pathologies
share several vicinal disorders such as coronary disease
and insulin resistance, no commonality with PD is
found, so that also at a lower significance threshold neu-
rological and metabolic disorders were distinct. More-
over, specific associations with diseases are unveiled. In
the obesity network, we find cushing syndrome,
cachexia, acromegaly, and polycystic ovary syndrome
(PCOS). Cushing syndrome is an endocrine disorder
caused by undue exposure to cortisol. Its symptoms
include weight gain and obesity. Like acromegaly, cush-
ing syndrome can be caused by pituitary adenoma,
which is the case in 70% of cushing syndrome inci-
dences [29]. Clinical associations were previously
reported for acromegaly and obesity [30] as well as for
obesity and PCOS [31,32]. Cachexia has manifestations
that are adverse to obesity, such as loss of weight. As
shown in Additional file 3, our analysis suggests ghrelin
Table 1 Disorders associated with obesity, Parkinson disease, T1DM and T2DM at a P-value threshold of 0.01 and an
overlap of at least 2 genes
Obesity Parkinson T1DM T2DM
Acromegaly Alzheimer Disease Coronary Disease Coronarya Artery Disease
Cachexia Amyotrophic Lateral Sclerosis Diabetes Mellitus Coronary Disease
Cardiomyopathy, Dilated Attention Deficit Disorder with Hyperactivity Diabetes Mellitus, Type 2 Diabetes Mellitus
Coronary Disease Bipolar Disorder Diabetic Nephropathies Diabetes Mellitus, Type 1
Cushing Syndrome Brain Ischemia Graft vs. Host Disease Heart Failure
Diabetes Mellitus Dystonia Hyperinsulinism Hypercholesterolemia
Diabetes Mellitus, Type 2 Epilepsy, Temporal Lobe Insulin Resistance Hyperinsulinism
Heart Failure Neurodegenerative Diseases Pancreatitis Hypertension
Hyperlipoproteinemia Type II Parkinsonian Disorders Sjögren’s Syndrome Insulin Resistance
Hypertension Schizophrenia Myocardial Infarction
Insulin Resistance Obesity
Obesity, Morbid
Polycystic Ovary Syndrome
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was recently discussed in several articles [33,34]. The
network connects obesity (yellow node) with vicinal dis-
eases (red nodes, see also Table 1) through common
causal genes (blue nodes). Besides GHRL, the set of cau-
sal genes shared by obesity and cachexia comprised
ADRB2, MC4R, and CNTF (Additional file 3). Further-
more, the T1DM vicinity reflects its immunological
etiology, whereas PD is associated exclusively with other
neurological disorders (Table 1). Graft vs. Host disease,
pancreatitis as well as Sjögren’ss y n d r o m ea r ei m m u n e
system-related disorders which, like T1DM, involve
immune response-driven tissue destruction. Connections
between PD and schizophrenia as well as attention defi-
cit disorder with hyperactivity are supported by dysregu-
lation of dopamine-dependent neurotransmission shared
by these morbidities [35,36], whereas clinical associa-
tions of PD with bipolar disorder and with dystonia
have been previously described as effects of PD therapy
with dopamine agonists, also suggesting common causal
mechanisms [37,38].
In summary, the statistical analysis of causal genes
enabled us to find meaningful disease associations.
Interestingly, many of these associations correspond to
clinical observations of comorbidities and known etiolo-
gical relationships between diseases as supported by
highlighted scientific literature. Examination of disease
clusters revealed characteristic biological functions
which confirm the causal mechanistic basis of inferred
disease relationships. Altogether, our findings suggest
that causal molecular mechanisms provide for an expe-
dient principle to gain further insight into the network
of human diseases.
Prediction of causal genes
Having a method to identify meaningful disease associa-
tions, our next goal was to apply disease similarities as a
starting point for causal gene prediction. Following our
previous results, we assumed that gene sets of associated
disorders potentially harbor novel mechanistic compo-
nents of the disease of interest. The short-list of candi-
date genes was then culled from associated pathologies
hypothesizing that frequent co-occurrence in causal
gene sets implies functional relationship with a known
disease gene (Methods).
In this work, we chose a similarity P-value of 0.01 and a
minimal overlap of two causal genes or diseases to infer
links between diseases or genes, respectively. The proce-
dure was employed to predict novel disease genes for
T1DM, T2DM and obesity, which are listed in Table 2.
By manual literature research we could verify the
majority of predictions as shown by the PubMed identi-
fiers of relevant research articles given next to corre-
sponding candidate gene symbols. Corroboration of our
predictions was least successful for T1DM with 6 of
13 candidate genes left unverified, whereas only 3 of
20 genes proposed to be involved in T2DM, namely
ADRB1, IL2, and ITGA2B, were not confirmed.
As an additional step, we performed network analysis
of signal transduction molecules encoded by known and
predicted causal genes using the network cluster algo-
rithm of ExPlain™ [39]. The algorithm constructs signal-
ing pathways connecting as many molecules from an
input set as possible with a distance constraint for reac-
tion cascades. As a result, input molecules are clustered
into networks of two or more molecules. These network
clusters can be visualized and subjected to other bioin-
formatic analyses [39]. In our pursuit, the application
served two purposes. Firstly, molecular pathways point
out potential mechanisms by which known and pre-
dicted causal components exert a common function.
Secondly, signaling cascades may allude to additional,
previously unknown constituents of disease mechanisms.
In the following, we examined network clusters of
known and predicted causal components of T1DM as
well as T2DM.
Table 2 Causal genes predicted for T1DM, T2DM and
obesity and supporting literature referenced by PubMed
identifiers
T1DM T2DM Obesity
Gene PubMed Gene PubMed Gene PubMed
AGT 18413222 ABCC8 17259403 AGTR1 15878965
12559865
AKT2 ADRB1 APOA2 17446329
APOA4 16770585 APOA1 17654446 APOA4
CD36 15737001 APOA4 17654446 APOB 10706596
CRP 15448085 APOE 12439646 CRP 11390329
10591334
CYP19A1 CBS 12198128 GCG 19597507
GCK CD44 19017033 GCK 18483479
HMGCR 17941871 ENPP1 17143316 GNAI2 17928396
IGF2 HGF 16759302 HNF1A
ITGA2B IGF1 15832492 IGF2
NOS3 19246226 IL2 ITGA2B
P2RY12 IRS2 9495343 LCAT
VEGFA 17513698 ITGA2B LDLR 10914685
LDLR 12716819 NR3C2 18427128
PAX6 19130035 P2RY12
19034419
PON1 10667477 RYR2 16793060
PROC 17971179 SSTR5 12943494
REN 15516153 XDH 17276354
RYR2 15044459
SOD1 18292963
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the following, we provide gene symbols in parentheses
where these differ from the protein names reported in
ExPlain™ networks. A small cluster consisted of the
known causal component CD154 (CD40LG) and the
predicted molecule alpha IIb-integrin encoded by
ITGA2B (Table 2), providing computational evidence
for a role of ITGA2B in T1DM. Additional file 4 shows
the larger cluster including ten known causal compo-
nents (red nodes) and the novel component IGF-2
(IGF2) (green node) connected by other molecules (blue
nodes) through activating (black arrows) or inhibitory
(red arrows) reactions. By manual literature research, we
verified involvement of SOCS3 [40], Jak1 (JAK1) [41],
a n dS H P - 1( P T P N 6 )[ 4 2 ]i nT 1 D M .N o t a b l y ,G r b - 1 4
(GRB14) and PTP1B (PTPN1) are known molecular
constituents of insulin resistance [43,44] and develop-
ment of PTP1B inhibitors for therapeutic modulation of
insulin sensitivity is an active field of research [45].
While PTP1B and Grb-14 functions were mainly
explored with regard to their causal role in T2DM and
obesity, the prevalence of insulin resistance in conjunc-
tion with type 1 diabetes has recently gained attention
[46,47].
We further obtained two network clusters of T2DM
molecules shown in Additional files 5 and 6. In a small
network (Additional file 5), known causal components
ADA and CD26 (DPP4) form a cascade with the pre-
dicted causal component CD44 (green node) connected
by RANTES (CCL5) (blue node), which harbors promo-
ter polymorphisms associated with type 2 diabetes [48].
The larger network (Additional file 6) comprises 19
known causal components (red nodes) and 5 predicted
components, namely activated protein C (PROC), alpha-
IIb integrin (ITGA2B), Cu-ZnSOD (SOD1), IRS-2 (IRS2)
and IL-2 (IL2) (green nodes). Moreover, scientific litera-
ture supports a mechanistic role of several network
components, such as PKCdelta (PRKCD) [49], PKCtheta
(PRKCQ) [50], GSK3 (GSK3B) [51], p85 (PIK3R1) [52],
Rac1 (RAC1) [53], p65PAK (PAK1) [54], Akt (AKT1),
PDK1 (PDPK1), and mTOR (MTOR) [55].
Taken together, disease and gene associations success-
fully predicted causal genes for obesity, T1DM, and
T2DM, and scientific literature verified the majority of
proposed candidates. Molecular network analysis of
T1DM and T2DM gene sets then suggested signal trans-
duction cascades connecting predicted and known cau-
sal proteins encoded by respective genes. Additional
constituents of causal disease mechanisms were inferred
along with molecular pathways and a good part of them
(more than 1/3) were supported by literature evidence.
Notably, many of the cited research articles investigated
respective causal components as therapeutic targets for
T1DM or T2DM. These results demonstrate the utility
of causal mechanism-based disease analysis for inference
of novel disease genes.
Evaluation of causal gene predictions
We used literature-verified causal genes that were pre-
dicted for obesity, T1DM, and T2DM (Table 2) as refer-
ence sets to calculate false positive and true positive
rates at different P-value thresholds in the range from
0.001 to 0.1. As before, the same P-value cut-off was
imposed on disease similarity as well as gene similarity
and a minimal overlap of two genes or diseases was
r e q u i r e d .F i g .( 4 A ,C ,a n d4 E )s h o w sr e c e i v e ro p e r a t o r
characteristics (ROC) (red curves) and plots of the pro-
portion of false positive predictions among all predicted
disease genes (blue curves). True positive rates were
estimated from literature-verified causal gene sets,
which comprised 12, 7, and 17 genes for obesity,
T1DM, and T2DM, respectively (Table 2). False positive
rates were based on all other, non-verified genes. In the
ROC plots, the location of P-value cut-off 0.01, that was
originally applied to obtain reference sets is indicated by
gray lines. ROC curves are supported by plots of the
proportion of false positives among all predicted disease
genes at a given threshold. Both quantities show that
the true positive rate grows faster than the false positive
rate with increasing P-value threshold. The ROC curves
present an idealized trend, since false positive rates were
calculated from a much larger number of genes than
true positive rates. Yet, in all three examples the propor-
tion of false positive genes decreased with more
stringent thresholds both above and below the reference
cut-off. According to this analysis, the best precision
values ranged from 80% to 90%. We defined the best
precision threshold as the P-value cut-off that achieved
prediction of a maximal proportion of true positives
while requiring at least one false positive gene. Optimal
precision values were 86% (6 true positive genes), 80%
(4 true positive genes), and 90% (9 true positive genes)
for obesity, T1DM, and T2DM, respectively. Hence,
disease similarities and causal gene comparison discrimi-
nated against false positive genes and selected for true
disease genes.
We examined how the number of predictions corre-
lated with P-value thresholds and observed an approxi-
mately linear dependence in all three examples (Fig. 4B,
D, and 4F). This shows that the P-values effectively con-
trolled the number of predictions, albeit the rates of
change were not the same for the three disorders.
Cross-validation (CV) was performed to evaluate the
robustness of our results with perturbed disease/gene
association data. We carried out 20 rounds of cross-vali-
dation for obesity, T1DM, and T2DM by removing 5
randomly chosen genes from their causal gene sets.
Poisson parameters were re-estimated for diseases and
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Page 8 of 19Figure 4 Characteristics of the method for disease gene prediction. The left side shows ROC curves and plots of the proportion of false
positives among predicted genes for obesity (A), T1DM (C), and T2DM (E). Numbers of predicted false positive genes obtained at P-value
thresholds from 0.001 to 0.1 are shown on the right side (B - obesity, D - T1DM, F - T2DM).
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5 random gene sets and 10
5 ran-
dom disease sets, respectively, using the modified asso-
ciation data. Subsequently, we predicted causal genes for
each of the disorders at a P-value threshold of 0.01 and
an overlap threshold of 2.
The bar plots in Fig. 5 list all genes that were pre-
dicted in the course of 20 cross-validation rounds and
show the fraction of samples in which the genes were
encountered. For all three disorders, the genes that were
predicted in the unmodified data set and were reported
in Table 2 (blue bars) also appeared in more than 50%
of the cross-validation samples, and the majority of
these genes was encountered more than 75% of the
time. While several genes were newly predicted during
cross-validation (white bars), none of them was pre-
dicted as often as those from the original set. Further-
more, most of the newly predicted genes were known
disease genes that had been removed from the causal
gene sets (red bars). Some new genes were incurred in a
considerable amount of samples such as APOE and
NOS3 in obesity (Fig. 5A), LDLR, APOE, and IL4 in
T 1 D M( F i g .5 B ) ,a sw e l la sP O M Ca n dC C L 2i nT 2 D M
(Fig. 5C). We think, that this variability can at least in
part be explained by the sampling of random disease or
gene sets in the empirical estimation of Poisson para-
meters. For instance, in the T2DM analysis CCL2 was
predicted in four cross-validation rounds due to similar-
ity with AGTR1 at P-values ranging from 8.77e-3 to
9.998e-3. Likewise, POMC was similar to the T2DM
gene SERPINE1 with P-values from 9.62e-3 to 9.97e-3
in 8 CV rounds. The proximity of these P-values to the
cut-off suggests the sampling process as the source of
that variability, because small changes in the regression
model could shift the estimated similarity P-value above
or below the threshold. Nevertheless, the method
robustly selected certain genes most of the time,
whereas there is a visible distinction to other, non-dis-
ease genes that were detected infrequently (Fig. 5).
Furthermore, we examined the recovery of left-out
disease genes and illustrate the obtained statistics in box
plots (Fig. 6). The method achieved recovery rates
between 30% and 60%, yet with large deviations. Hence,
the procedure could only identify a minor part of left-
out genes. We speculate, that this performance is due to
the sparseness of the underlying data and the recovery
rates reflect the proportion of known disease genes that
could be identified given the imposed thresholds.
In summary, cross-validation demonstrated that the
method robustly produced a limited set of genes which
preferably included the originally reported gene predic-
tions. We could observe effects of sampling random dis-
ease or gene sets in the empirical estimation of Poisson
Figure 5 Cross-validation of disease gene predictions. Each bar plot shows all genes predicted during cross-validation for obesity (A), T1DM
(B), and T2DM (C). Blue bars indicate genes that were predicted with the unperturbed set of disease/gene, some of which could be verified
with literature evidence (dark blue). Red bars correspond to known disease genes omitted from cross-validation samples, whereas white bars
signify genes newly predicted in the validation.
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would mitigate the variability inherent to the sampling
procedure. This does not represent a major drawback,
since the regression analysis needs to be conducted only
once and parameter estimates can then be used in sub-
sequent comparisons. Furthermore, we assume that
recovery of known disease genes was limited to certain
fraction of the causal gene sets due to the low coverage
of underlying disease/gene associations. This suggests
that other types of information such as molecular inter-
actions could complement the predictions entirely based
on disease/gene associations.
We therefore tested the utility of combining predic-
tions derived from disease/gene associations with a
method that employs molecular interactions. The Gene-
Wanderer is a tool that applies a global network dis-
tance measure to rank candidate genes according to
their context to known disease genes in a network [56].
The algorithm assigns a distance value to candidate
genes based on a random walk with restart (RWR),
which reflects how well candidate genes are connected
to modules of disease genes [56]. RWR distance values
are higher for genes that are well connected to known
disease genes and were successfully applied to prioritize
candidate genes [56]. We compared the ranks of
distance values obtained with and without inclusion of
genes predicted on the basis of disease/gene associations
for known disease genes that were omitted from the
cross-validation samples. Thus, for each of the left-out
disease genes, we calculated RWR distance values using
either only the truncated set of disease genes or pre-
dicted genes in addition. In the following, we denote
RWR distance values as network score. An interaction
network containing 10486 genes and 109089 interac-
tions was compiled from the IntAct [57], BioGRID [58],
and Reactome [17] databases (Additional file 7). We
used the ranks of network scores of the test disease
genes among all genes of the network to compare the
performance with and without addition of genes pre-
dicted by disease/gene associations in each CV sample.
An improved rank of the network score would
enhance the possibility to correctly prioritize a disease
gene, because it would increase its chance to be highly
ranked among candidate genes. Ranks were calculated
as 10486-r, where r is the conventional rank order, so
that higher values correspond to better network scores.
Fig. 7 shows the results of this analysis for obesity (Fig.
7 A ) ,T 1 D M( F i g .7 B ) ,a n dT 2 D M( F i g .7 C ) .D o t sr e p r e -
sent disease genes that were omitted from CV sets and
are located according to the highest of the network
Figure 6 Box plots of recovery rates estimated by cross-validation. The box plots of distributions of the fraction of known disease genes
that were omitted from causal gene sets of obesity, T1DM and T2DM and recovered by disease gene prediction.
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genes (x-axis) and the corresponding rank difference (y-
axis). Rank differences for test disease genes are positive
if the addition of predicted genes to the attenuated dis-
ease gene set improved the rank of the network score.
The plots show that the genes predicted by disease/gene
associations enhanced the network scores of many test
genes. The cases where the ranks decreased (values
below zero on the y-axis) mostly involved genes with a
low network score, which were thus not well connected
to other disease genes in the interaction network. In
addition, the decrease was never lower than -1000. On
the contrary, inclusion of predicted genes could substan-
tially improve the network scores for several genes.
Importantly, higher network scores showed a clear ten-
dency for improvement. For instance, in the T2DM
comparison, ranks of network scores greater than 0.001
were always better than with the attenuated disease
gene set alone (Fig. 7C). Since higher network scores
signify a smaller global distance to the set of input dis-
ease genes, this demonstrates that addition of genes that
were predicted on the basis of disease/gene associations
supported the network scores of test genes in the vici-
nity of modules of disease genes. These results show
that disease gene prediction can benefit from combining
disease associations with analysis of molecular interac-
tions. Often only a handful of causal genes are known
for a disorder. Our analysis suggests that consideration
o fg e n e sf r o md i s e a s e st h a ta r el i k e l yt oi n v o l v es i m i l a r
molecular mechanisms can enhance the prediction of
novel disease genes.
Discussion
Knowledge about components of causal mechanisms has
proven useful to analyze relationships between human
diseases. The definition of causal genes applied in the
BKL includes genotype associations, yet also covers
other sources of evidence for involvement in causal
molecular systems. This may be of importance taking
into account that the activity of gene products in the
context of molecular networks may bias the ability of
genes to harbor pathological mutations as shown by sev-
eral studies [59-61]. Probably, more or less complex pat-
terns of genetic variation contribute to every disease.
However, their functional effects become manifest in
molecular interactions, where networks of proteins, yet
also protein/DNA interactions, take an important part
and genetic alterations are one of many possibilities to
induce derangement [62].
On the foundation of causal disease/gene associations,
we built a method to quantify the similarity of two dis-
eases that accounts for unequal frequencies of genes in
the entire set of associations. To provide a familiar and
intuitive quantity, the presented method reports a
P-value for the overlap of causal gene sets. At standard
P-value thresholds, 0.001 and 0.01, the statistical analysis
revealed meaningful disease associations as demon-
strated by constructing a map of human diseases, GO
analysis of disease clusters and inspection of vicinal dis-
orders for obesity, T1DM, T2DM and PD at the lower
threshold.
Human disease networks were previously studied with
respect to physiological disease classes [10,14]. Here, we
first constructed the disease map and afterwards demon-
strated that biological processes coincided with well-
known attributes of clustered disorders as confirmed by
manually curated GO biological process annotation of
the BKL as well as GO annotations available through
the DAVID Functional Annotation Tool. Furthermore,
we observed that the giant component of our disease
Figure 7 Network scores and rank differences for tested disease genes. Network scores and associated rank differences compared for
reduced disease gene sets only and with inclusion of genes predicted on the basis of disease/gene associations. Dots represent known disease
gene omitted from cross validation set generated for obesity (A), T1DM (B), and T2DM (C). See text for further description.
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T2DM clustered components of the cardiometabolic
syndrome. Notably, the disease vicinities that were
explored in more detail reflected not only similarities
between obesity, T1DM, and T2DM, but captured also
specific relationships such as connections to immunolo-
gical disorders in the T1DM vicinity. When we applied
causal disease associations to predict new disease genes,
the majority of predictions proposed for obesity, T1DM,
and T2DM could be supported by references to scienti-
fic literature. Altogether, our results corroborate that
the inferred disease associations reflect common mole-
cular mechanisms and indicate applications for disease
gene prediction as well as disease classification and
definition.
Limitations of current standard classifications were
previously challenged with regard to molecular or com-
plex systems approaches [63,64]. Protein-protein interac-
tions and molecular pathways have been employed to
identify disease relationships [13,14]. So far our method
for disease comparison left molecular interactions
unspecified and addressed only the overlap of causal
gene sets. A first step towards incorporating molecular
networks into our analysis was taken by clustering cau-
sal components in signal transduction networks. As evi-
denced by scientific literature, the network clusters
Figure 8 Distribution of disease/gene associations and regression analyses of gene overlap as a function of random gene set size. (A)
Distribution of disease/gene associations. The plot shows how many genes (y-axis) are linked to a certain number of diseases (x-axis). The
majority of genes (about 86%) in the BKL data set are not associated with more than 5 disorders, whereas other genes are much more strongly
connected. These differences in disease links per gene were taken into account by generating random sets containing genes with the same
frequency as the original data. (B-C) Regression functions obtained for calcinosis (B), T2DM (C), and prostatic neoplasms (D). Given a causal gene
set, the mean overlap with a random gene set is a linear function of the random gene set size. Deviations from regression curves are observed
for small and large random gene sets, which are supported by fewer samples as shown by corresponding data point weights and predictive
intervals.
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peutic targets. Furthermore, we translated the analysis
of disease associations and of causal gene associations
into a method to select for new disease genes. While
disease gene prediction entirely based on experimentally
verified disease/gene associations faced limitations origi-
nating from the sparseness of the available data, we
could show that a combination of disease associations
and molecular network analysis enhanced the possibility
to identify new disease genes. Incorporation of molecu-
lar interactions is therefore an important area for further
development, where greater fidelity with molecular sys-
tems that underlie disease mechanisms can be achieved.
We would like to point out that our method for pre-
diction of causal genes relied on four cut-off values
consisting of a P-value and a minimal overlap parameter
in the first and the second step (Fig. 9). It may be diffi-
cult to tune each of the parameters to achieve optimal
results. Throughout this work, we set identical cut-offs
for disease and gene similarity and confined analyses to
standard P-value thresholds (0.001 or 0.01). Further-
more, the overlap threshold was always set to a small
value of 2 with the purpose of controlling a minimal
level of shared causal genes or diseases. We think that
with this setting the overlap cut-off sufficiently comple-
ments the P-value. As demonstrated, the number of
false positives grows linearly with the P-value threshold
(Fig. 4), so that this parameter lends itself to further
adjust the algorithm. One possibility is to choose a
number of predictions admissible for validation and to
Figure 9 Workflow for causal gene prediction. The schema illustrates the workflow to predict causal genes for a disease of interest. In step 1,
similar diseases were gathered on the basis of the disease similarity threshold (similarity P-value and overlap threshold). For example, if obesity
were the disease of interest and a P-value of 0.01 as well as a minimal overlap of two causal genes were applied as similarity cut-off, this step
would select the vicinal disorders of obesity described in Table 1. Step 2 only considered genes of similar diseases which satisfied the similarity
threshold with known causal genes of the disease of interest. These genes were eventually predicted as causal genes of the disease of interest
(Step 3).
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this type of approach our method offers, in addition to
using a common value for disease and gene similarity,
the possibility to fix the disease similarity threshold (e.g.
to 0.01) and to subsequently rank predicted causal genes
according to overlap P-values with known disease genes.
Furthermore, the method achieved best precision for
obesity, T1DM, and T2DM at P-value thresholds of
0.005, 0.003, and 0.01, respectively. At a P-value of
0.005 the observed precision for T1DM and T2DM was
still at least 75%. This indicates that the range from
0.001 to 0.01 is suitable to choose a threshold for causal
gene prediction and suggests 0.005 as a possible starting
point.
In our efforts to verify the inferred disease associa-
tions, we were able to highlight many instances of
known clinical associations and comorbidities, suggest-
ing that these are special cases of related pathologies
sharing causal mechanisms which also connect them
etiologically. Interestingly, these findings inversely con-
firm a previous study, where co-occurrence of disorders
in medical records was used to predict genetic overlap
[9]. Validation of disease co-prevalences often requires
laborious population studies. According to the results of
this work, the decision to mount a study could be sup-
ported by testing hypotheses about disease associations
computationally. Simultaneously, shared causal compo-
nents provide insight into the molecular basis of etiolo-
gical disease relationships and suggest potential
diagnostic markers.
So far, different methods have been proposed to inves-
tigate human disease associations. A main difference lies
in the representation of disease entities by features that
are eventually compared to obtain a figure of similarity.
While this work focused on genes that were manually
classified as causal disease genes, other approaches used
clinical characteristics, phenotypes, or genes and path-
ways [5,8,14]. Each choice of feature representation
involves advantages and disadvantages with respect to
quality, coverage, or detail of information. For instance,
manual curation promises greater quality than computa-
tionally derived annotation, but its coverage is often
inferior. Furthermore, associated genes capture disease
components in finer detail than descriptions of clinical
characteristics, but we assume that for a disease the lat-
ter are more often defined than associated genes. It is
therefore of importance to compare the different
approaches to recognize and validate strengths and
weaknesses.
To the best of our knowledge, no reference set has
been established to systematically examine the ability of
different methods to correctly identify disease associa-
tions, so that a necessary step towards such a compari-
son is to assemble a set of known disease links.
Another future direction will be to combine different
levels of information such as causal genes, affected bio-
logical processes, and clinical characteristics to gain
further insight into disease subtypes and corresponding
mechanisms. Of interest are phenotypically similar dis-
ease subtypes that present different molecular mechan-
isms as well as similarities on the molecular level that
cannot be mapped to known clinical characteristics.
Identification of such disease subtypes and of “hidden”
disease similarities may open new avenues to develop
therapeutic approaches for respective disorders.
Conclusions
We developed a novel approach to analyze human dis-
ease associations and demonstrated its utility in several
application areas. Causal molecular mechanisms present
a unifying principle for disease classification and defini-
tion, analysis of clinical disorder associations, as well as
prediction of disease genes, therapeutic targets and diag-
nostic markers. According to the definition of causal
disease genes applied in this study, these results are not
restricted to genetic disease/gene relationships. This
may be particularly useful for the study of long-term or
chronic illnesses, where pathological derangement due
to environmental or as part of sequel conditions is of
importance and may not be fully explained by genetic
background. The possibility to identify common mole-
cular mechanisms for clinically associated disorders
enables further insight into disease interactions. First
steps in that direction were presented in this work for
obesity and diabetic disorders, as constituents of the car-
diometabolic syndrome. An important conclusion from
this work is that components of molecular mechanisms
characterize associated diseases. Using this knowledge
enables identification of disease associations, which
reflect common molecular mechanisms, and provides
for a starting point to identify missing causal compo-
nents. Making use of such disease associations and con-
sideration of knowledge about molecular interactions
can be combined to handle limitations imposed by the
sparseness of experimentally verified, curated disease/
gene associations. Future lines of research will include
incorporation of molecular interactions into the method
for disease comparison and development of software
tools that exploit the findings of this work.
Methods
Causal disease/gene associations
Manually collected information on causal disease/gene
associations was obtained from the BIOBASE Knowl-
edge Library™ (BKL) [19]. The BKL groups disease/gene
associations into four types, correlative, causal, preventa-
tive, and negative, depending on the conclusion that can
be drawn from a relevant research article. In this study,
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ventative type. Causal relationships are derived from
experiments, which confirm or suggest the hypothesis
that a gene encodes a product whose deranged activity
entails a disease or a certain condition as part of a dis-
ease. The derangement may be inheritable or emerge
during disease onset or progression. Preventative dis-
ease/gene associations additionally evince that experi-
mental evidence is available for a therapeutic effect of
modulating the deranged activity. In this article, we
denote the respective genes as causal genes. To ensure a
certain level of annotation for disease comparison, we
considered only disease entities with at least five causal
genes. The eventual data set comprised 375 diseases and
3051 causal genes connected by a total of 9871 disease/
gene associations. Data used in this study are available
upon request.
The BKL specifies diseases using MeSH descriptors
[4], which constitute a hierarchy of broader and nar-
rower subject headings. The hierarchical structure of
MeSH descriptors allows for incorporation of disease-
related scientific information into the knowledgebase,
even when the disorder to which an article pertains is
not distinguishable at the most specific level. Inference
of disease associations performed in this work ignored
hierarchical dependencies. Hence, it was anticipated that
similarities between some disorders merely reflect the
underlying MeSH structure.
Disease comparison
We estimated the statistical significance of the number
of common causal genes to quantify similarity between
two diseases. The one-tailed Fisher test, which is often
used to evaluate enrichment of GO categories, could be
applied to identify high numbers of shared genes. How-
ever, the Fisher test assigns the same sampling probabil-
ity to all genes. As shown in Fig. 8A, this assumption
does not hold for the BKL data set. Most genes (about
86%) were connected to not more than five diseases,
whereas other genes had much higher numbers of asso-
ciations, up to the extreme of 78 links (about 21% of the
375 diseases) to tumor necrosis factor (TNF). Conse-
quently, disorders involving TNF are more likely to
overlap than other diseases whose causal genes may
have only few associations. We therefore developed a
procedure that takes this property of the data set into
account. To this end, a sampling approach was imple-
mented to generate random gene sets in which causal
genes occur with the same frequency as in the original
data.
It turned out that for a given disease, the mean over-
lap with random gene sets follows a linear function of
the random gene set size, as shown in Fig. 8 for calcino-
sis (Fig. 8B), T2DM (Fig. 8C), and prostatic neoplasms
(Fig. 8D) with 5, 89, and 393 causal genes, respectively.
To estimate the statistical significance of an observed
number of shared genes, we therefore predicted the
mean overlap using a regression model and used the
conditional mean estimate to calculate a P-value assum-
ing a Poisson law. A large number (200 K) of random
gene sets was generated by sampling one out of all 375
diseases with probability 1/375 for each of the 3051 cau-
sal genes and assigning the gene to the respective gene
set if the sampled disease was associated with that gene.
Each causal gene set, representing a disease of the origi-
nal data, was compared to the collection of random
gene sets to subsequently obtain a model for the depen-
dence of the mean number of common genes on the
size of a random gene set by weighted linear regression.
The latter was conducted as follows. Let A and R denote
the causal gene sets of a disease from the original data
and a random gene set, respectively. The data for
regression analysis consisted of points P(X; Y )a n dc o r -
responding weights W(X) as defined in (1-3), where |X|
denotes the cardinality of a set.
XR = (1)
Y
AR
RX
RR X
=
∩
=
∑
= {} #:
(2)
WX R R X () # : == {} (3)
We implemented a step-wise procedure to select a
suitable regression model. T h ep r o c e d u r ee x a m i n e da l l
linear models specified by equation (4), where ˆ  is the
estimated mean number of common genes, n is the
number of genes in a random gene set, and ˆ  repre-
sents a parameter of the regression function. Models
with or without intercept ˆ 0 were treated explicitly by
the extra coefficient c.
ˆˆ ˆ ,. .  =⋅ + ⋅ ∈ () ∈{}
= ∑ cn k ck k
k
k
 0
1
1
01 1 4
max
;; ; max (4)
Iterating over all eight combinations of c and kmax, the
model with lowest Akaike information criterion (AIC)
value [65] was chosen among all models whose function
was both non-decreasing and predicted only positive
mean responses over the whole range of gene set sizes
of the original data. Eventually, we used regression esti-
mates to calculate the statistical significance for a num-
ber of shared genes assuming a Poisson distribution for
gene overlap counts using equation (5), where x denotes
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sents the Poisson distribution parameter obtained from
the regression model.
PX x e
k
kx
≥ () =−
−
≤< ∑ 1
0
ˆ ˆ
 
!
(5)
As Poisson parameter estimation was performed for
each of 375 diseases, pairwise disease comparison ensues
two P-values. We therefore summarized P-values by cal-
culating their geometric mean as defined in (6) in order
to obtain a single quantity for each disease pair. In
equation (6), A and B denote gene sets of diseases from
BKL and PA and PB represent P-values calculated with
respective models.
PX x P X x
PXx x AB
A
B
≥ () =⋅ ≥ ( () ()
+≥ ) () ) () =∩
exp( log
log
1
2
;;
(6)
The functions lm and summary.lm of the R statistical
computing environment [66] were used to estimate
regression models and to calculate AIC values.
In the course of disease gene prediction, the described
procedure was adopted to estimate P-values for the
number of diseases shared by causal genes.
Statistical analysis of biological processes
Functional characteristics of disease clusters were analyzed
with Gene Ontology Biological Processes [15]. Among the
three GO vocabularies for biological processes, cellular
components, and molecular functions we selected the bio-
logical process ontology, because its terms were deemed to
best represent molecular mechanisms that may be targets
of derangement in disease. Biological process terms
describe biological objectives accomplished via one or more
ordered assemblies of molecular functions. In the majority
of cases, more than one gene contributes to a biological
process, whereas GO molecular functions denote biochem-
ical activities of individual genes [15]. Several biological pro-
cesses are well known targets of disease mechanisms such
as cell cycle (GO:0007049) in cancer or immune response
(GO:0006955) in auto-immune or infectious diseases.
In order to compare the importance of certain GO
biological processes among disease groups, we first cal-
culated one-tailed Fisher test P-values to quantify
enrichment of GO categories in respective gene sets and
assigned a category to the disease group with lowest
Fisher test P-value. Biological functions more strongly
associated with one disease group compared to others
were found by calculating preponderance values accord-
ing to equation (7). The preponderance values were
used to rank categories allocated with a certain disease
group. In (7), the Pi are Fisher test P-values of N disease
groups arranged in non-decreasing order. The prepon-
derance value Prep is the smallest difference of P-values
weighted by the relative proportion of the most signifi-
cant P-value after logarithmic transformation.
Prep GO P P
P
Pi
i
() = () () () ⋅ ()
() ∑
Δ log ,log
log
log
10 1 10 2
10 1
10 (7)
with
iN P P P P N =≤ ≤ ≤ < 11 12 1 .. .. ;;
This analysis was carried out with manually curated
GO biological process annotations from the BKL [19] as
well as with GO annotations available through the
DAVID Functional Annotation Tool [27,28].
Prediction of causal disease genes
The approach to analyze overlap statistics was applied to
construct a method for prediction of causal genes for a dis-
ease of interest, which is described in Fig. 9. In the first
step, we selected diseases that were similar to the disease of
interest at a certain threshold. The selected diseases were
hypothesized to potentially share molecular mechanisms
with the disease of interest, so that their associated genes
could present novel candidate genes. In the second step, we
tested for similarity between genes associated with the dis-
ease of interest and genes of selected disorders. Here, we
assumed that causal genes that overlap in a significant num-
ber of disorders may function in a common mechanism.
Genes that were associated with a disease selected in the
first step and shared a sufficient number of disorders with a
known disease gene were then predicted as causal genes for
the disease of interest. In this work, gene comparisons were
carried for genes with at least 5 disease associations yielding
a set of 706 genes linked to a total of 1060 diseases.
Molecular network clusters
Signal transduction networks of molecules encoded by
known and predicted causal genes were constructed by
the network cluster tool of ExPlain™ [36]. The algorithm
searches for shortest paths of maximally three reaction
steps between input molecules. Information about sig-
naling reactions is taken from the TRANSPATH™ data-
base [67]. The ExPlain tool identifies networks, so-called
network clusters, which connect a maximal number of
input molecules given the distance constraint.
Network layout and visualization
Layout and visualization of disease networks as well as
disease/gene networks were performed with the yED
graph editor developed by yWorks [68].
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